Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic co…

No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III ...

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in ...

No. 52 / 2026Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III ...
PR Newswire

Seguritech to Attend the 19th NENA 9-1-1 International Congress for Emergency Call Centers

Seguritech, a leading global provider of intelligent public safety and situational awareness technologies, today announced it will ...
Astrobiology

Direct Molecular-scale Insight Into Soluble Organic Matter From The Murchison and Aguas Zarcas Meteorites

Organic material in the Murchison and Aguas Zarcas meteorites preserves molecular records of early solar system chemistry and ...
MarketScreener

Zealand Pharma A/S : announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic ...

In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 wee ...

Seguritech participará en el XIX Congreso Internacional para Centros de Llamadas de Emergencia de NENA 9-1-1

Seguritech, proveedor líder mundial de tecnologías inteligentes de seguridad pública y conocimiento de situaciones, ha anunciado hoy que participará en el XIX Congreso Internacional para Centros de Ll ...